On Jan. 12, the U.S. Food and Drug Administration (FDA) expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have metastasized and whose tumors have the BRCA gene mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer.
Read more via Fda.gov.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
